Table 1.
Baseline characteristics of postmenopausal women by oral estrogen therapy (ET) use.
| Women with oral ET use at baseline and at follow-up | Women with no ET use at baseline and no ET use at follow-up | |
|---|---|---|
| n=324 | n=382 | |
| Age (years)* | 56.5 (7.6) | 58.7 (9.0) |
| Race/ethnicity* | ||
| Caucasian | 66 | 53 |
| African-American | 16 | 28 |
| Hispanic | 13 | 16 |
| Asian | 4 | 3 |
| Type of menopause* | ||
| Bilateral oophorectomy | 42 | 20 |
| Natural menopause | 39 | 67 |
| Age ≥ 55 years and hysterectomy | 19 | 16 |
| Years since final menstrual period | 14 (9) | 15 (10) |
| Baseline weight (kg)* | 87.6 (17.8) | 91.0 (19.7) |
| Baseline waist circumference (cm)* | 101 (14) | 104 (14) |
| Baseline BMI (kg/m2)* | 33.3 (6.5) | 34.6 (6.8) |
| Baseline fasting insulin levels (IU/l)* | 23.4 (12.0) | 26.4 (16.0) |
| Baseline fasting plasma glucose (mg/dl)* | 104 (7) | 107 (8) |
| Baseline 2-hour glucose | 166 (18) | 164 (17) |
| Baseline follicle stimulating hormone (IU/l)* | 34.8 (22.5) | 55.3 (26.6) |
| Baseline sex hormone binding globulin (nmol/l)* | 85.3 (77.0) | 33.2 (18.3) |
| Baseline total estradiol (pg/ml)* | 17.6 (14.8) | 8.5 (8.0) |
| Baseline bioavailable estradiol (pg/ml)* | 8.6 (9.4) | 6.0 (6.4) |
Means (SD) or percentages shown; medians (interquartile ranges or IQR) shown for sex hormones.
*
indicates significant difference (p<0.05) between ET users and non-users.